Observational studyJAMA network open2019
Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition.
Observational study in JAMA network open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Pharmacokinetic equivalence of CT-P17 to high-concentration (100 mg/ml) reference adalimumab: A randomized phase I study in healthy subjects.Clinical and translational science · 2021Trial
- Drivers of infliximab biosimilar uptake: A comparative analysis of new biosimilar initiations versus switching in a national rheumatology registry.Health services research · 2025Article
- Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022.Arthritis & rheumatology (Hoboken, N.J.) · 2024Article
- Drugs anticipated to be selected for the Medicare Drug Price Negotiation Program in 2025.Journal of managed care & specialty pharmacy · 2024Article
- Anti-TNFα in inflammatory bowel disease: from originators to biosimilars.Frontiers in pharmacology · 2024Review
- Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Article
- Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Article
- Recent Advances in Small Molecule Inhibitors for the Treatment of Osteoarthritis.Journal of clinical medicine · 2023Review
- Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis.Journal of managed care & specialty pharmacy · 2023Article
- Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis.ClinicoEconomics and outcomes research : CEOR · 2023Review
- Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.PloS one · 2023Article
- Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population.Journal of managed care & specialty pharmacy · 2022Article
- Estimating Potential for Drug Budget Reallocation Following Expiration of Exclusivity of Pharmaceutical Products.Journal of health economics and outcomes research · 2022Article
- Estimating Discounts for Top Spending Drugs in Medicare Part D.Journal of general internal medicine · 2021Article
- Association of Drug Rebates and Competition With Out-of-Pocket Coinsurance in Medicare Part D, 2014 to 2018.JAMA network open · 2021Article
- Real-life drug persistence in patients with rheumatic diseases treated with CT-P13: a prospective observational cohort study (PERSIST).Rheumatology advances in practice · 2021Article
- Trends in list prices, net prices, and discounts of self-administered injectable tumor necrosis factor inhibitors.Journal of managed care & specialty pharmacy · 2021Article
- Association Between Filgrastim Biosimilar Availability and Changes in Claim Payments and Patient Out-of-Pocket Costs for Biologic Filgrastim Products.Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2020Article
- Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018.JAMA · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.